Hypofractionated RT Effective for Localized Prostate Cancer

Share this content:
Hypofractionated radiotherapy at a dose of 60 Gy in fractions is non-inferior in localized prostate cancer.
Hypofractionated radiotherapy at a dose of 60 Gy in fractions is non-inferior in localized prostate cancer.

Hypofractionated radiotherapy at a dose of 60 Gy in fractions is non-inferior to conventional radiotherapy using 74 Gy in 37 fractions for the treatment of patients with localized prostate cancer after 5 years' follow-up, a study published in the journal The Lancet Oncology has shown.1

Because prostate cancer might have high radiation-fraction sensitivity that gives a therapeutic advantage to hypofractionated therapy, researchers compared the efficacy and safety of conventional radiotherapy with hypofractionated therapy.

For this phase 3 CHHiP trial, investigators enrolled 3216 patients from 71 centers; each patient enrolled had localized prostate cancer. Participants were randomly assigned 1:1:1 to conventional (74 Gy administered in 37 fractions over 7.4 weeks) or 1 of 2 hypofractionated schedules (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks). All approaches were delivered with intensity-modulated techniques; most patients received 3 to 6 months of neoadjuvant and concurrent androgen suppression.

At a median follow-up of 62.4 months, the 5-year biochemical or clinical failure-free rate was 88.3% (95% CI, 86.0-90.2) in the 74 Gy group, 90.6% (95% CI, 88.5-92.3) in the 60 Gy group, and 85.9% (95% CI, 83.4-88.0) in the 57 Gy group.

Researchers found that 60 Gy was non-inferior to 74 Gy (hazard ratio, 0.84; 90% CI, 0.68-1.03; P = .0018), though 57 Gy was not non-inferior to 74 Gy (hazard ratio, 1.20; 90% CI, 0.99-1.46; P = .48).

Long-term adverse events were similar between the hypofractionated radiotherapy arms and the conventional group. Investigators did not observe a significant difference in the cumulative incidence of adverse events within 5 years of treatment.

RELATED: Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance

The estimated cumulative 5 year incidence of grade 2 or worse bowel and bladder adverse events was 13.7% and 9·1% in the 74 Gy group, 11.9% and 11.7% in the 60 Gy group, 11.3% and 6.6% in the 57 Gy group, respectively.

The findings suggest that hypofractionated radiotherapy at 60 Gy in 20 fractions can be recommended as a new standard of care for external-beam radiotherapy of localized prostate cancer.                      

Reference

  1. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial [published online ahead of print June 20, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)30102-4.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters